StemCell Therapy

The global market for bioseparation reached $18.4 billion in 2015. This market is expected to increase from $19.0 billion in 2016 to nearly $24.0 billion in 2021 at a compound annual growth rate (CAGR) of 4.7% for 2016-2021.

Report Scope:

The market for bioseparation systems is growing rapidly across all regions. Bioseparation purifies biological products on a largescale. The report focuses on the global market of bioseparation systems and provides an updated review, including basic design and its applications, in various arenas of biomedical and life science research.

The scope of the study is global. BCC Research analyzes each market, new products and advancements, technologies involved, market projections and market shares. The geographical regions covered in the report are North America, Europe and emerging markets. The emerging market covers all countries like India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, and Canada, among others.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/11796

The bioseparation techniques that are covered in this report are chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, microarray, labonachip, biochip, and magnetic separation. Among chromatography techniques, liquid chromatography is the most active market.

Also included in the report are relevant patent analysis and comprehensive profiles of companies that lead the bioseparation systems market. Key players include Thermo Fisher Scientific, Agilent Technologies Inc., BioRad Laboratories, Danaher Corp., Qiagen N.V., Merck KGaA GmbH, and Waters Corp. among others.

Report Includes:

An overview of the global market for the commercial applications of biotechnology separation systems by product, by company, and by geographic region. Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021. Examination of the various segments of the market, new applications for separation technology, and overall industry trends, as well as the separation process for a variety of biomolecules, including proteins, RNA, and DNA. Identification of one of the major drivers for the separations system market: the development by the biomedical and pharmaceutical industries of proteins that can be used as biotherapeutic agents against a number of human diseases; another factor that will contribute to growth is the recognition of this technology in emerging markets such as Japan and the Pacific Rim countries. Assessments of trends based on a number of parameters, including projected sales for existing products, new product introductions, and expanded indications for existing products.

Report Summary

Biomolecular separation is an important technique used in many industries including biopharmaceutical, biotechnology, food, and agriculture, among others. Biomolecular products, like protein and DNA, have become an important segment of the healthcare industry. New techniques to analyze complex biological mixtures and the genetic engineering technology have helped produce biological molecules with modified features. These biomolecular products are widely used in diagnosis and in the treatment of various life threatening diseases such as cancer and diabetes, among others.

Separation systems for commercial biotechnology involve techniques including chromatography, centrifugation, electrophoresis, membrane filtration, flow cytometry, magnetic separation, microarray, biochip and labonachip. These techniques are widely used to separate biomolecular products.The global bioseparation system market is expected to grow at a CAGR of 4.7% through 2021. Liquid chromatography had the largest revenue in the bioseparation technique market in 2015. This market is at a rise because of its usage in research and clinical laboratories. The rising demand for biosimilars is leading to the growth of chromatographic separations and thus increasing the market. The newer techniques used in liquid chromatography are highly acceptable in the bioseparation system such as ultraperformance liquid chromatography (UPLC), ultrahigh performance liquid chromatography (UHPLC) and twodimensional liquid chromatography (2DLC). Membrane filtration is another growing segment in the biopharmaceutical and biotechnology industry. The use of filtration is in demand for producing more efficient and optimized biological products, which, in turn, drives the membrane filtration market.

Upcoming new technologies in this industry include biochip and labonachip. The biochip market is increasing due to the demand for genetic diagnostics where a biochip helps perform an analysis in a fraction of a second, for example, decoding genes.

The market for labonachip is increasing due to the new technologies available, like microfluidics and nanofluidics. Labonachip is a handy technique as the analysis of the sample can be performed at the same point where the sample is generated. It is in demand because of its contribution in the oncology sector.

Major players in the global bioseparation system market include Agilent Technologies Inc., Alfa Laval, Danaher Corp., GEA Westfalia Separator Group GmbH, GE Healthcare, Hitachi Koki Co. Ltd., Merck KGaA, Miltenyi Biotec Inc., PerkinElmer Inc., Qiagen N.V., Shimadzu Corp., Sysmex Partec GmbH, Thermo Fisher Scientific Inc., Waters Corp. and 3M Company.

The global bioseparation system market is expected to reach to nearly $24.0 billion by 2021, growing at a CAGR of 4.7%. The market in the United States is expected to reach nearly $9.3 billion by 2021, while Europe will reach $6.0 billion. Europe had revenue of about $4.8 billion in 2015, which is anticipated to grow at a CAGR of 3.5% through 2021. Emerging markets is expected to reach nearly $8.7 billion by the end of 2021. Emerging markets led in 2016 followed by the United States. The rising population in India and China are increasing the healthcare spending and therefore causing a rise in the industry. Also, some liberty from the stringent regulatory laws of the Japanese government is expected to yield apositive impact on in the emerging markets. New technologies being implemented in life science research and diagnosis, as well as increasing healthcare spending by the United States government are some of the key factors for the growth in this region and the U.S. is expected to surpass emergingmarkets in 2021.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11796

See the article here:
Separation Systems For Commercial Biotechnology Market Overview on Future Threats the COVID-19 - Cole of Duty

Global Molecular Weight MarkerMarket is expected to grow at a CAGR of 11% to reach US$ XX million in 2026.

The growth is coupled with the increased popularity of personalized medicines for the treatment of chronic diseases and genetic disorders. Personalized medicines involve the application of molecular weight markers for the study of individuals genome, genes, and diseases. Thus, growing adoption of personalized medicines along with the escalating focus on molecular biology research is expected to boost the demand for molecular weight marker products.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/10962/

Technological advancement in molecular biology products, such as PCR and NGS along with high-quality molecular weight Global Molecular Weight Marker is another major factor contributing towards growth. The recent advancement in these products enables provision of a clearer background and sharp bands. Thus, the demand for molecular weight marker products is expected upsurge soon, which is expected to boost growth.

North America dominated the molecular weight markers industry with the largest revenue share, owing to the presence of many large research laboratories and biotechnology firms such as CELGENE CORP. and Amgen Inc. In addition, the highly developed healthcare and research infrastructure in this region have fuelled the Global Molecular Weight Marker growth.

Asia Pacific is estimated to exhibit the highest CAGR during the forecast period, owing to rising focus of CROs and biotechnology companies in this region for drug discovery and development. The CROs are focusing on Asian countries such as China and India for clinical trials owing to less stringent government regulations and the availability of skilled professionals. These are some of the factors projected to boost the regional Global Molecular Weight Marker growth.

Prestained markers were the highest revenue-generating segment in 2017, due to the large application of this product for genomics and proteomics research. Other factors include an ability to provide more accurate molecular weight determinations of the sample over a wide molecular weight range. Thus, the popularity of this product is increasing, which is expected to propel the growth of the Global Molecular Weight Marker.

Global Molecular Weight Marker

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/10962/

The objective of the report is to present comprehensive Global Molecular Weight Marker Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Molecular Weight Marker Market North America for Asia Pacific dynamics, structure by analyzing the market segments, and project the Global Molecular Weight Marker Market North America for Asia Pacific size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Molecular Weight Marker Market North America for Asia Pacific make the report investors guide.Global Molecular Weight Marker Segmentation

Global Molecular Weight Marker Market, By Products

o DNA markers Below 50 bp 50 bp to 100 bp 100 bp to 1 kb 1 kb to 5 kb Above 5 kb

o Protein markers Below 10 kDa 10 k Da to 100 kDa 100 k Da to 200 kDa Above 200 kDa

o RNA Markers Global Molecular Weight Marker Market, By Type

o Prestained markerso Unstained markerso Specialty markersGlobal Molecular Weight Marker Market, By Applications

o Nucleic acid applications PCR Sequencing Northern blotting Southern blotting Molecular cloning Others

o Proteomics applications Western blotting Gel extraction OthersGlobal Molecular Weight Marker Market, By End-Use

o Academic and research instituteso Pharmaceutical and biotechnology companieso CROso Others

The above data will be provided for following regions/countries from 2013-2024 (USD Million)

North Americao U.S.o Canada

Europeo Germanyo UKo Franceo Spaino Italy

Asia Pacifico Chinao Indiao Japano Australia

Latin Americao Argentinao Brazilo Mexico

Middle East and Africao South Africao Saudi Arabia

MAJOR TOC OF THE REPORT

Chapter One: Molecular Weight Marker Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Molecular Weight Marker Market Competition, by Players

Chapter Four: Global Molecular Weight Marker Market Size by Regions

Chapter Five: North America Molecular Weight Marker Revenue by Countries

Chapter Six: Europe Molecular Weight Marker Revenue by Countries

Chapter Seven: Asia-Pacific Molecular Weight Marker Revenue by Countries

Chapter Eight: South America Molecular Weight Marker Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Molecular Weight Marker by Countries

Chapter Ten: Global Molecular Weight Marker Market Segment by Type

Chapter Eleven: Global Molecular Weight Marker Market Segment by Application

Chapter Twelve: Global Molecular Weight Marker Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Molecular Weight Marker Market Report at: https://www.maximizemarketresearch.com/market-report/global-molecular-weight-marker-market/10962/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Connect With us at LinkedIn LinkedIn

Connect with us at Facebook Facebook

Contact With Us at Twitter Twitter

Read the original:
Global Molecular Weight Marker Market : North America Is Expected To Account For Higher Market Share Of... - Azizsalon News

COVID-19 Impact Analysis of Plant Biotechnology Services Market

[Los Angeles], [United States], May 2020, The Plant Biotechnology Services Market research report includes an in-sight study of the key [Global Plant Biotechnology Services Market Size, Status and Forecast 2020-2026] market prominent players along with the company profiles and planning adopted by them. This helps the buyer of the Plant Biotechnology Services report to gain a clear view of the competitive landscape and accordingly plan Plant Biotechnology Services market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Plant Biotechnology Services specifications, and company profiles. The Plant Biotechnology Services study is segmented by Module Type, Test Type, And Region.

The market size section gives the Plant Biotechnology Services market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Plant Biotechnology Services industry over a defined period.

Download Full PDF Sample Copy of Report: https://www.qyresearch.com/sample-form/form/1527927/global-plant-biotechnology-services-market

Key Manufacturers of Plant Biotechnology Services Market include: Thermo Fisher Scientific Inc., Agilent Technologies, GenScript Biotech Corporation, Eurofins Scientific SE,

The research covers the current market size of the [Global Plant Biotechnology Services Market Size, Status and Forecast 2020-2026]and its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc., by product type Genomics Services, Analytical Chemistry, Cellular Imaging, Forage Analysis, Transformation Services, by applications Research Institutes, Pharmaceuticals Companies, Biotechnology Companies in overall market. The in-depth information by segments of Plant Biotechnology Servicesmarket helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the [Global Plant Biotechnology Services Market Size, Status and Forecast 2020-2026].

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of [Global Plant Biotechnology Services Market Size, Status and Forecast 2020-2026]. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Read Detailed Index of full Research Study: https://www.qyresearch.com/index/detail/1527927/global-plant-biotechnology-services-market

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Plant Biotechnology Servicesin these regions, from 2012 to 2022 (forecast), covering

Please Check below Chapters to display the [Global Plant Biotechnology Services Market Size, Status and Forecast 2020-2026].

There are 15 Chapters to display the [Global Plant Biotechnology Services Market Size, Status and Forecast 2020-2026].

Chapter 1, to describe Definition, Specifications and Classification of Plant Biotechnology Services, Applications of Plant Biotechnology Services, Market Segment by Regions;

Chapter 2, To analyse the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Plant Biotechnology Services, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Thermo Fisher Scientific Inc., Agilent Technologies, GenScript Biotech Corporation, Eurofins Scientific SE, ), Sales Analysis (Thermo Fisher Scientific Inc., Agilent Technologies, GenScript Biotech Corporation, Eurofins Scientific SE, ), Sales Price Analysis (Thermo Fisher Scientific Inc., Agilent Technologies, GenScript Biotech Corporation, Eurofins Scientific SE, );

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc., Plant Biotechnology Services Segment Market Analysis (Genomics Services, Analytical Chemistry, Cellular Imaging, Forage Analysis, Transformation Services);

Chapter 7 and 8, to analyse the Plant Biotechnology Services Segment Market Analysis (Research Institutes, Pharmaceuticals Companies, Biotechnology Companies) Major Manufacturers Analysis of Plant Biotechnology Services;

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type [Type], Market Trend [Research Institutes, Pharmaceuticals Companies, Biotechnology Companies];

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyse the Consumers Analysis of Plant Biotechnology Services;

Chapter 12, to describe Plant Biotechnology Services Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Plant Biotechnology Services sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Continued here:
Plant Biotechnology Services Market Emerging Trends, Global Demand and Business Opportunities 2020 to 2026 - Weekly Wall

STAMFORD, Conn., May 26, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Julie Hambleton, M.D. to the Companys Board of Directors.

We are delighted to welcome Julie to the SpringWorks Board of Directors. She is a leading oncology drug developer whose experience will further strengthen our board and provide valuable insight as we advance our diversified pipeline of targeted oncology programs in rare oncology indications, multiple myeloma and metastatic solid tumors, said Saqib Islam, Chief Executive Officer of SpringWorks Therapeutics.

Dr. Hambleton, M.D. added, I am impressed by the breadth and quality of targeted oncology programs that SpringWorks is advancing both as a monotherapy for patients with rare diseases, and as combination therapies for patients with highly prevalent cancers. SpringWorks has built leading drug development capabilities and has already demonstrated strong execution across their portfolio. I look forward to working with the team and sharing my experience to guide the current and future development programs.

Julie Hambleton, M.D. is a senior biotechnology executive with over 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs), and Special Protocol Assessments (SPAs). Dr. Hambleton served as Senior Vice President, Chief Medical Officer, Head of Development at IDEAYA Biosciences, an oncology medicine company, until her retirement on April 30, 2020. Previously, she was Vice President, Head of U.S. Medical at Bristol-Myers Squibb, overseeing Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios. Previously, she served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics and Vice President, Clinical Development, at Clovis Oncology. Dr. Hambleton began her industry career at Genentech, most recently as Group Medical Director, Global Clinical Development, leading a cross-functional group conducting Phase 2 and 3 trials of Avastin. Dr. Hambleton also serves on the board of directors of IGM Biosciences, Inc., a publicly traded biotechnology company, and of Arch Oncology, a privately-held biotechnology company.

Dr. Hambleton completed her medical and hematology-oncology training at the University California, San Francisco, where she then served on faculty from 1993 to 2003. She received a B.S. from Duke University, and M.D. from Case Western Reserve University School of Medicine and was Board-certified in Hematology and Internal Medicine.

About SpringWorks TherapeuticsSpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, please visit http://www.springworkstx.com. Follow SpringWorks Therapeutics on social media: @SpringWorksTx and LinkedIn.

Originally posted here:
SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors - Citybizlist Real Estate

CLEVELAND Anyone who has driven on the shoreway near downtown has come just a few feet away from a series of brick buildings that, in some cases, are just feet away from the road.

What many people dont know is that just a few feet from all those passing cars is a company helping doctors fight cancer insight a nondescript but wide open building.

Thats actually what were were looking for, said GenomOncology CEO Brad Wertz talking about the companys new space.

He says GenomOncology was looking for a place where they could build a modern, start-up type office space.

From the street, First Energy Stadium is to the north, with the Flats, Warehouse District, and Public Square a short walk away in other directions.

You start with a cool, comfortable, enjoyable place to work that we believe is highly productive, highly collaborative and you build out from there based on what youre in the mood for, said Wertz.

Wertz says the space is home base for Cleveland-based employees, a place to visit for the few employees who work remote, and allows the company to host clients in from out of town, after the coronavirus passes.

Thats all important for a bio-technology company looking to attract all kinds of workers. Additional space on other floors gives the company options to expand in the future.

GenomOncology Chief Technology Officer Ian Maurer says the demand for their work continues to increase as they help more doctors.

How do we take DNA data for cancer and process it, analyze it, and understand what the variances mean, said Maurer explaining the work GenomOncology does.

He says more research is revealing more about the human body, helping doctors fight cancer more effectively. Since theres more information to keep track of, GenomOncology has created software that helps doctors find the right specialized treatment based on the best knowledge of the day.

Were not about replacing pathologists, said Maurer. Were about making them better. Were about democratizing this information, this knowledge so everyone across the country can give the best care to their patients.

All just a few feet off the shoreway.

Have you ever noticed something interesting in Northeast Ohio and wondered, Heywhats going on there?

Us, too. We love learning more about what shapes the world around us -- the buildings, the spaces and the ways we move between them.

Next time you're wondering about some building, project or piece of land, send me an email at Kevin.Barry@wews.com and I'll look into it for a possible story.

See the original post:
Biotechnology company just feet away from the shoreway helping doctors diagnose and treat cancer - News 5 Cleveland

The emergence of COVID-19 has put a spotlight on the $258 billion biotechnology industry.

Across the globe, companies large and small are racing to develop a vaccine.

After all, an effective vaccine is the only surefire path back to normal.

And, of course, that means big profits for the first to market.

Thats why the minute a headline comes out about a new development, stock prices surge higher. TakeModerna Inc. (Nasdaq: MRNA), for example. Following a report on Monday of positive results in a test on just eight individuals, MRNA stock jumped 20%. That brings the total gains for the stock to over 150% in just two months!

You can see why biotech stocks get a bad reputation as purely speculative plays. Company profits and the fate of stock gains rest solely on the outcome of clinical trials.

But if you dig deeper, you can find companies with broad product portfolios that generate billions in sales and profits.

And the truth is that the biotech industry offers an incredible value opportunity at the moment and thats why you should act now.

Ever since peaking in mid-2015, the Nasdaq Biotechnology Index (NBI) has traded in a range that previously never surpassed its prior high.

But industry profits continued to grow over that time. And the result is that valuations have become cheap especially compared to the broader stock market.

Right now, the price-to-earnings (P/E) ratio on the biotech index is 16.5. Thats below its 10-year average of 16.9.

At the same time, the P/E ratio on the S&P 500 Index is 20.9, which is well above its own 10-year average of 15.9.

That means biotech stocks are trading at a 21% discount to the stock market when, historically, theyve traded at a premium.

And now that this sector is garnering tons of attention, investors are realizing this as well. In fact, the group is being pushed above key price levels.

Check out the chart below to see the price action Im talking about:

(Click here to view larger image.)

This chart shows the price ofiShares Trust Nasdaq Biotechnology ETF (NYSE: IBB)over the past 10 years. IBB is an exchange-traded fund (ETF) that tracks the biotech sector. And as shown by the trend line, stocks in this sector are just now staging a key breakout to new highs.

What makes this breakout even more significant is the price consolidation of the past five years. That means a powerful move higher is in the works.

Cheap valuations coupled with surging momentum make biotech stocks an excellent pick in this frothy stock market.

So act quickly and pick up shares in IBB to profit from biotechs breakout!

Best regards,

Clint Lee

Research Analyst,The Bauman Letter

See more here:
Grab This ETF to Profit From Biotech's Breakout - iShares Biotechnology - Banyan Hill Publishing

Click here to get sample of the premium reporthttps://www.quincemarketinsights.com/request-sample-60943?utm_source=campaign=Pooja/AZ

The report commences with brief information of the globalBiotechnology media, sera and reagentsmarket. This report sets the tone for the rest of the report, providing users the scope of the report. The report includes important facts and statistics on the globalBiotechnology media, sera and reagentsmarket.

A globalBiotechnology media, sera and reagentsmarket is provided in this next section. This involves market introduction and a standard product definitionBiotechnology media, sera and reagents. This section provides readers with market value and year-by-year growth. Annual growth gives readers a wider view of growth patterns during the forecast period.

The report focuses on macro-economic, demand and supply drivers, constraints, and important patterns. In order to better inform the decision-making system of clients, the impact analysis for weighted average model-based growth drivers is present in the report.

The report will be updated on a number of market opportunities, which leadingBiotechnology media, sera and reagentscompanies can benefit from, to provide readers with up-to-date information on the latest developments on the globalBiotechnology media, sera and reagentsmarket. As the healthcare sector develops continuously, it is vital forBiotechnology media, sera and reagentsmanufacturers to develop key business strategies to keep a track of current developments and trends. This section provides detailed insights into the sourcing of raw materials, supply chain, regulatory approvals, price analyses, list of distributors and cost structure.

Considering the broad spectrum of the internationalBiotechnology media, sera and reagentsmarket, QMIs report provides important insights, analysis and forecast segmentation. Data are divided into product type, method, technology and region on the globalBiotechnology media, sera and reagentsmarket. This segment-specific analysis also offers a country-specific forecast taking all key parameters of the globalBiotechnology media, sera and reagentsmarket into consideration.

The last section of the report covers the competitive landscape of the globalBiotechnology media, sera and reagentsmarket to give readers an overview of company analysis and market players. This competitive intelligence is based on the categories of suppliers throughout the entire value chain and their participation in the globalBiotechnology media, sera and reagentsmarket.

QMI is committed to providing its clients with impartial and independent solutions for market research. Each QMI report is assembled after an extensive and comprehensive research. In order to give you the most comprehensive and accurate information, we use a mix of proven and innovative methodology. Primary research, secondary research, business research, focused interviews and social media analysis are our main sources of research.

Get Scope of the actual premium reporthttps://www.quincemarketinsights.com/request-toc-60943?utm_source=campaign=Pooja/AZ

Market Segmentation:

By Type: Media Sera ReagentBy Application: Cancer Research Biopharmaceuticals Regenerative Medicine & Tissue Engineering OthersBy End-User: Biotechnology & Pharmaceutical Companies Academic Institute Research LaboratoryBy Region: North America North America, by CountryUSCanadaMexico North America, by Type North America, by Application North America, by End-User Western Europe Western Europe, by CountryGermanyUKFranceItalySpainThe NetherlandsRest of Western Europe Western Europe, by Type Western Europe, by Application Western Europe, by End-User Asia Pacific Asia Pacific, by CountryChinaIndiaJapanSouth KoreaAustraliaIndonesiaRest of Asia Pacific Asia Pacific, by Type Asia Pacific, by Application Asia Pacific, by End-User Eastern Europe Eastern Europe, by CountryRussiaTurkeyRest of Eastern Europe Eastern Europe, by Type Eastern Europe, by Application Eastern Europe, by End-User Middle East Middle East, by CountryUAESaudi ArabiaQatarIranRest of Middle East Middle East, by Type Middle East, by Application Middle East, by End-User Rest of the World Rest of the World, by CountrySouth AmericaAfrica Rest of the World, by Type Rest of the World, by Application Rest of the World, by End-User

Major Companies:

Key Players:GE Healthcare, Bio-Rad laboratories Inc., Merck KGaA (Sigma Aldrich), Sartorius AG, HiMedia Laboratories Pvt., Ltd, Lonza Group Ltd, Merck & Co., Inc.

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us

Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109,Pune, Maharashtra 411028Phone: +91 706 672 5858/+1 208 405 2835/+91 706 672 4848Email:sales@quincemarketinsights.comWeb:www.quincemarketinsights.com

Read the rest here:
Biotechnology Media, Sera and Reagents Market Study and Future Prospect | Forecast To 2028 - Azizsalon News

Increasingly inexpensive genetic sequencing and engineering tools could upend everything from health care to fuel.

Why it matters: This bio revolution could lead to a world that is more sustainable and even extend human lifespans. But its full extent is dependent on social acceptance and carries serious risks as well.

What's happening: The scientific reaction to COVID-19 illustrates the rapid change in the biological sciences, says Michael Chui, a partner at McKinsey Global Institute (MGI). "For SARS-CoV-2, it took a matter of weeks between identifying the new disease and sequencing it, compared to months for the original SARS virus."

But the response to COVID-19 only scratches the surface of what the bio revolution may make possible.

How it works: The chief driver of these changes is the rapid drop in cost of the tools that enable us to understand and increasingly manipulate the stuff of life, including in our own bodies.

The catch: Because biology is far more regulated than the field of artificial intelligence, the speed of the bio revolution will depend not just on science, but on public attitudes. The MGI report estimates 70% of the total impact could hinge on consumer, societal, and regulatory acceptance.

The bottom line: AI gets much of the attention, but advances in biotechnology are poised to be just as momentous. Put those two fields together and they will transform the world.

Read this article:
A coming bio revolution is poised to change the world - Axios

LGC Biosearch Technologies

All of the product type and application segments of the Agricultural Biotechnology market included in the report are deeply analyzed based on CAGR, market size, and other crucial factors. The segmentation study provided by the report authors could help players and investors to make the right decisions when looking to invest in certain market segments.

The Essential Content Covered in the Agricultural Biotechnology Market Report :

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report is a compilation of different studies, including regional analysis where leading regional Agricultural Biotechnology markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Agricultural Biotechnology market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Agricultural Biotechnology markets. It also provides information on lucrative opportunities available in key regional Agricultural Biotechnology markets.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=35624&utm_source=COD&utm_medium=001

Table of Content

1 Introduction of Agricultural Biotechnology Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Agricultural Biotechnology Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Agricultural Biotechnology Market, By Deployment Model

5.1 Overview

6 Agricultural Biotechnology Market, By Solution

6.1 Overview

7 Agricultural Biotechnology Market, By Vertical

7.1 Overview

8 Agricultural Biotechnology Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Agricultural Biotechnology Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/agricultural-biotechnology-market/?utm_source=COD&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Agricultural Biotechnology Market Size, Agricultural Biotechnology Market Trends, Agricultural Biotechnology Market Growth, Agricultural Biotechnology Market Forecast, Agricultural Biotechnology Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Mobile Data Protection Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Activated Carbon Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Visit link:
Agricultural Biotechnology Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and Forecast to 2026 - Cole of...

Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.

In contrast to all current vaccination approaches against SARS-Co-V-2, the approach of Mirror Biologics Inc., the US subsidiary of Jerusalem-based Immunovative Therapies Ltd., addresses the phenomenon of viral evolution. In the Journal of Translational Medicine, Michael Har-Noy and collegues describe the companies technical rationale for development of a universal anti-viral vaccine designed to protect immunocompromised humans and eldery adults from COVID-19 and any future novel virus outbreaks.

The patent-pending technology called AlloPriming is designed so that a series of injections of bioengineered Th1-cells, called AlloStim, could provide protection from any future viral infection, including progression of the current outbreak of COVID-19 infection, and any future variants of the causative SARS-CoV-2 virus or the next Disease X. The technology primes the elderly immune system to respond to viruses in the same manner as a healthy younger adult immune system would respond it remodels the aging immune system in order to reverse immunosenescence and protect against chronic inflammations. A Phase I/II clinical protocol has been prepared for testing this concept in healthy adults over 50 years in age and is currently under review by the US FDA.

The major focus for vaccine development against viruses are currently strategies that introduce inactivated whole viruses, or pieces of viruses, or viral genetic material to teach the immune system to make antibodies, which bind to the virus. The aim is to elicit antibodies which neutralize the virus by blocking entry into host cells. According to the authors, allo-priming, which triggers call-based immunity, provides a back-up in case vaccination strategies to elicit neutralising antibody protection fails or fails to protect the vulnerable elderly population.

Allo-priming is performed using activated, intentionally mismatched, ex vivo differentiated and expanded living Th1-like cells (AlloStim) derived from healthy donors. Preclinically, multiple intradermal injections of AlloStimcreated a dominate titer of allo-specific Th1/CD8-T-cytotoxic memory cells in circulation, replacing the dominance of exhausted memory cells of the aged immune system. Upon viral encounter, by-stander activation of the allo-specific memory cells caused an immediate release of interferon gamma (IFN-), stopping viral transcription and leading to by-stander activation of innate cellular effector cells and activation of cross-reactive allo-specific CD8-T-cytotoxic lymphocytes.

A youthful immune response is believed to be most capable of clearance of viral infections before the infection progresses to serious disease", said Reuven or, who co-authored the publication. He sees the approach as complementary to current vaccination approaches. But in deed it is more:

All current vaccination approaches have not been successful in protecting against emergent viruses, such as HIV, hepatitis C, Zika, dengue and the pandemic SARS and MERS coronaviruses, which mutatate and adapt very rapidly to its hosts. In contrast to childhood diseases they will not provide lifelong protection because they are based on an approach viral evolution, which does not occur in pathogens such as measles or other childhood diseases. For this reason, current vaccine technology platforms may not timely produce a protective vaccine against COVID-19 or could result in a vaccine that becomes obsolete after a viral mutation.

What is currently widely ignored: traditional vaccines could make rapidly mutating and adapting pathogens more aggressive. Under normal conditions, viral pathogens never become extremely deadly because they only spread if most of their hosts survive the infection. As vaccines create a selection advantage for viruses, which could enter and reproduce themselves ultrarapidly in the host cell, they might trigger a kind of vaccine-driven evolution, which would make viruses more deadly and devasting as postulated for the case of Marek's disease vaccines a neoplastic disease of poultry.

Lead author Michael Har-Noy commented: "While there is great optimism regarding current clinical trials investigating protective vaccines against COVID-19, there is a very real possibility that none of the vaccine candidates under investigation will prove to provide long-term protection from COVID-19, and some vaccine candidates may even make symptoms worse. Even in the event that an effective vaccine is timely developed, such a vaccine likely would not be as effective in providing protective immunity in the elderly. If allo-priming is proven to work as designed, a single series of shots could protect against the current pandemic as well as any future pandemic.

The rest is here:
Vaccine to protect from any viral infection - European Biotechnology

Shire

All of the product type and application segments of the Nanoparticles in Biotechnology and Pharmaceuticals market included in the report are deeply analyzed based on CAGR, market size, and other crucial factors. The segmentation study provided by the report authors could help players and investors to make the right decisions when looking to invest in certain market segments.

The Essential Content Covered in the Nanoparticles in Biotechnology and Pharmaceuticals Market Report :

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report is a compilation of different studies, including regional analysis where leading regional Nanoparticles in Biotechnology and Pharmaceuticals markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Nanoparticles in Biotechnology and Pharmaceuticals market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Nanoparticles in Biotechnology and Pharmaceuticals markets. It also provides information on lucrative opportunities available in key regional Nanoparticles in Biotechnology and Pharmaceuticals markets.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=COD&utm_medium=001

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=COD&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Nanomagnetic Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

More:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and...

A perfect mix of quantitative & qualitative Agriculture Biotechnologymarket information highlighting developments, industry challenges that competitors are facing along with gaps and opportunities available and would trend in Agriculture Biotechnologymarket. The study bridges the historical data from 2014 to 2019 and estimated until 2025.

The Agriculture BiotechnologyMarket report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Agriculture BiotechnologyIndustry.

Downlaod Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6319455/agriculture-biotechnology-market

The Top players are ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences, Eurofins, Evogene, Global Bio-chem Technology, Syngenta, KWS Saat, Marina Biotech, Monsanto, .

Market Segmentation:

On the basis of the end users/applications, Transgenic crops market, Synthetic biology-enabled products market

Download Free Sample PDF along with few company profileshttps://inforgrowth.com/sample-request/6319455/agriculture-biotechnology-market

Be the first to knock the door showing the potential that Agriculture Biotechnologymarket is holding in it. Uncover the Gaps and Opportunities to derive the most relevant insights from our research document to gain market size.

A major chunk of this Global Agriculture BiotechnologyMarket research report is talking about some significant approaches for enhancing the performance of the companies. Marketing strategies and different channels have been listed here. Collectively, it gives more focus on changing rules, regulations, and policies of governments. It will help to both established and new startups of the market.

The study objectives of this report are:To analyze global Agriculture Biotechnologystatus, future forecast, growth opportunity, key market, and key players.To present the Agriculture Biotechnologydevelopment in the United States, Europe, and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market, and key regions.

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6319455/agriculture-biotechnology-market

Major Points from Table of Contents

1 Agriculture Biotechnology Agriculture Biotechnology Market Overview2 Agriculture Biotechnology Market Competition by Manufacturers3 Production Capacity by Region4 Global Agriculture Biotechnology Market by Regions5 Production, Revenue, Price Trend by Type6 Global Agriculture Biotechnology Market Analysis by Application7 Company Profiles and Key Figures in Agriculture Biotechnology Business8 Agriculture Biotechnology Manufacturing Cost Analysis9 Marketing Channel, Distributors and Customers10 Market Dynamics11 Production and Supply Forecast12 Consumption and Demand Forecast13 Forecast by Type and by Application (2021-2026)14 Research Finding and Conclusion15 Methodology and Data Source.

ENQUIRE MORE ABOUT THIS REPORT AT https://inforgrowth.com/enquiry/6319455/agriculture-biotechnology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Go here to see the original:
Agriculture Biotechnology Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top...

Global Biotechnology Reagents Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Biotechnology Reagents Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Sample

Global Biotechnology Reagents Market is valued at USD 71.25 Billion in 2018 and expected to reach USD 121.06 Billion by 2025 with the CAGR of 7.86% over the forecast period.

Increasing prevalence of diseases such as hepatitis B with growing research and development expenditure bybiotechnologytherapeutics and rising number of biotechnology firms globally are expected to boost the market over the forecast period.

Biotechnology reagents are the substances or compounds used to detect or create an additional substance in order to provide a test reading. Hence, the biotechnologies are used in research fields of genetics, molecular biology, diagnosis, immunology, bioscience and in education. The various uses of biotechnology reagents are; fluorescent microscopy, DNA analysis, immuno phenotyping and cell cycle analysis. The biotechnology reagents industry depends on the growth of biotechnology instrumentation market. Biotechnology reagents market includes technologies such as IVD, PCR, transfection, gene expression and cell culture. The basis of technology market is section into analytical reagents and life science reagents. The Life science technologies include in vitro diagnostics, unit culture, polymerase chain reaction and analytical technologies includes flow cytometry, electrophoresis, mass spectrometry and chromatography. The healthcare biotechnology is usually to improve medicines due to the advantages and pieces of knowledge it provides such as understanding the genetic composition of the human species, foundational structure of hereditary diseases manipulation and repairing of damaged genes to cure diseases. As the researchers might see the engineering of a supercharged flu virus as a perfectly reasonable way to better understand and thus fight the flu, the public might see the drawbacks as equally obvious the virus could escape, or someone could weaponize the research and the advanced genetic tools that some are considering for mosquito control could have unforeseen effects, possibly leading to environmental damage. Although the risks of biotechnology have been fretted over for decades, the increasing pace of progress from low cost DNA sequencing to rapid gene synthesis to precision genome editing suggests biotechnology is entering a new realm of maturity regarding both beneficial relevance and more worrisome risks.

Global Biotechnology Reagents Market report is segmented on the basis of type, application, and by regional & country level. Based on type, global biotechnology reagents market is classified as the Life science and analytical. Based upon application, global biotechnology reagents are classified into protein synthesis and purification, gene expression, DNA and RNA analysis and drug testing.

The regions covered in this biotechnology reagents market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of biotechnology reagents is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Biotechnology Reagents Market Report-

Some major key players for Global Biotechnology Reagents Market are Life Technologies, Bio-Rad, Thermo Fisher Scientific, Water Corporation, Sigma-Aldrich Agilent Technologies Inc., Beckman Coulter, Roche, Abbott and others.

Global Biotechnology Reagents Market Dynamics

The rapidly increasing use of biotechnology reagents in therapeutics, basic research and its commercialization are the major factors responsible for the growth of this market. According to the World Health Organization (WHO) in 2017, prevalence of hepatitis B estimated about 27 million people 10.5% of all people estimated to be living with hepatitis B were aware of their infection, while 4.5 million around 16.7% of the people diagnosed were on treatment. Hence, the rising prices of DNA sequencing is predictable to serve this sector as a high impact rendering growth is expected to encourage researchers and manufacturers to increase R&D initiatives targeted at understanding genetic variations and developing therapeutic solutions for chronic diseases with large global prevalence such as cardiovascular diseases, diabetes, and cancer. According to the World Health Organization (WHO) in 2015, the estimates that in 257 million people were living with chronic hepatitis B infection as surface antigen positive, the hepatitis B resulted in an estimated 887 000 deaths, mostly from cirrhosis and hepatocellular carcinoma is primary liver cancer. In addition, the high investments in R&D activities, growing biomedical research, increasing number of biotechnology firms and advancement in stem cell research have contributed to the growth of the biotechnology reagents market.

The biotechnology organizations such as the department of biotechnology (DBT) with government funded institutions and other autonomous organizations representing the biotechnology sector, promote funding to support R&D and innovative produce development endeavors. One of the major challenges faced by this market use of biotechnology reagents in the field of drug discovery is an emerging market where proteomics, DNA chips, combinatorial chemistry, and high throughput screening enjoy the spotlight. In addition, high price of biopharmaceuticals may likely to restrain the growth of the biotechnology reagents market. Moreover, increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology corporation can provide various opportunities for the further growth of the market. The technological advancements and new product launches in health care and life science industries to life science reagents are an integral part of any clinical diagnostic laboratory and pharmaceutical & biotechnology industry. The recent technological advancements in molecular biology, life sciences, and biotechnology has brought about drastic changes in various fields such as medical diagnostics, drug discovery, personalized medicines, forensic sciences, and clinical research & development of the biotechnology reagents market.

Global Biotechnology Reagents Market Regional Analysis

Geographically,North America dominates the global biotechnology reagents market & incurs the highest expenditure for global R&D. According to the World Health Organization (WHO) in 2018, the chronic diseases in the United States are about 133 million Americans 45% of the population have at least one chronic disease. In addition, rising ongoing research in biological sciences considerable investments by various biotechnology companies and the consistently increasing utilization of biotechnology reagents in the market due to the continuing research and outsourcing activities in the field of life science in this region are also supplementing the market growth.

TheAsia Pacific is expected to show a lucrative growth rate during the forecast period due to increasing research and outsourcing activities in life science field. However, the regionlarge population, presence of emerging economies such as China and India, large number of elderly individuals in Japan presents significant opportunities for global players in these countries. Adoption of technologically advanced products in Japan, China, South Korea, Malaysia, and Singapore are likely to fuel the growth of the life science reagents market in this region. Moreover, increased investment by leading pharmaceutical and biotechnology companies in India and China, and rapidly increasing number of hospitals and diagnostic laboratories in the region boost the growth of the biotechnology reagents market in the region.

Key Benefits for Global Biotechnology Reagents Market Report

Global market report covers in depth historical and forecast analysis.

Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global market report helps to identify opportunities in market place.

Global market report covers extensive analysis of emerging trends and competitive landscape.

By Type

By Application

By Regional & Country Analysis

Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=12804&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Biotechnology Reagents Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Biotechnology Reagents Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Biotechnology Reagents Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Biotechnology Reagents Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Biotechnology Reagents Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Biotechnology Reagents Market.

Market Forecast: Here, the report offers a complete forecast of the Global Biotechnology Reagents Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Excerpt from:
COVID 19 PANDEMIC: Biotechnology Reagents Market is poised to achieve continuing growth During Forecast Period 2020-2026 - Cole of Duty

A rating of 9 puts Therapix Biosciences Ltd - ADR (TRPX) near the bottom of the Biotechnology industry according to InvestorsObserver. Therapix Biosciences Ltd - ADR's score of 9 means it scores higher than 9% of stocks in the industry. Therapix Biosciences Ltd - ADR also received an overall rating of 22, putting it above 22% of all stocks. Biotechnology is ranked 10 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 22 would rank higher than 22 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Therapix Biosciences Ltd - ADR (TRPX) stock is down -2.31% while the S&P 500 is up 0.05% as of 11:03 AM on Tuesday, May 19. TRPX is lower by -$0.01 from the previous closing price of $0.42 on volume of 654,488 shares. Over the past year the S&P 500 has gained 4.05% while TRPX is lower by -87.27%. TRPX lost -$2.40 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more:
Where Does Therapix Biosciences Ltd - ADR (TRPX) Stock Fall in the Biotechnology Field? - InvestorsObserver

PHOENIX--(BUSINESS WIRE)-- BioLab, Inc., a regenerative biotechnology company, today announced a partnership with Red One Medical that will help veterans and active military members access breakthrough wound healing and regenerative medicine.

Red One Medical is private sector innovation partner of Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), it provides advanced medical and pharmaceutical technologies that improve patient care for America's military veterans. BioLab Sciences is working with Red One Medical to distribute regenerative medicine products and MyOwn Skin, a novel biotechnology that can accelerate the healing of severe burns, chronic wounds, diabetic foot ulcers, and other difficult-to-heal wounds.

Nearly one in four veterans has diabetes, and as such, the need for an innovative wound care solution is critical to treat non-healing diabetic ulcersthe leading cause of lower-limb amputations in non-combat veterans.

Were constantly on the lookout for innovative products to speed wound healing in veteran and military hospitals," said Red One Medical CEO and Founder Charles Pollak. "We want our veterans to receive top quality care, and MyOwn Skin takes wound care to the next level by leveraging a patient's own skin to quickly grow skin grafts in a new, non-invasive way."

MyOwn Skin leverages a very small sample of a patient's skin and blood taken through a non-surgical procedure to reproduce three, 100cm2 skin grafts within a week. MyOwn Skin eliminates the need for traditional skin grafts which require surgical procedures to remove large areas of healthy skin from other parts of a patients body, often resulting in additional wounds requiring care and healing time.

We are on a mission to help patients and providers access regenerative medicine products that help the body achieve optimal performance, said BioLab Sciences President and CEO Bob Maguire. As the VAs private sector innovation partner, Red One Medical is in a unique position to help advance the delivery of care to our nations veteran and military patients. This partnership is one step forward in that direction.

Along with MyOwn Skin, which is now one of the most advanced products in Red One Medical's wound care portfolio, the company will also distribute BioLab Sciences amniotic allograft membrane, amniotic liquid allograft and other regenerative products that promote healing for wound, orthopedic, respiratory and ophthalmic care. The products will be available to the DoD and VA health system, which includes more than 9 million veterans at approximately 1,700 facilities.

About BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin, a remarkable biotechnology that leverages a small sample of a patient's own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week. Learn more at http://www.biolabsciences.net/.

About Red One Medical

Red One Medical is a private sector innovation partner of Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals. Red One Medical identifies and delivers advanced medical and pharmaceutical technologies that transform care for Americas military veterans. Located in Savannah, GA, Red One Medical is a CVE-certified Service Disabled Veteran Owned Business (SDVOSB) and SBA-certified Historically Underutilized Business Zone (HUBZone) company. It donates a portion of profits to charities that support veterans, military families and their communities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005189/en/

See more here:
BioLab Sciences Partners with Red One Medical to Provide Transformative Wound Healing Products to Veterans and Active Military - BioSpace

The research report on Biotechnology Separation Systems market is a comprehensive analysis of this business space and entails all the key aspects of the industry including net revenue estimates, present renumeration, periodic deliverables, segmental share, market size, and market trends.

A brief assessment of the behavior pattern of the Biotechnology Separation Systems market over the forecast timeline has been cited in the report. Critical parameters such as growth drivers as well the expected growth rate followed during the study period are also documented in the report. It further elaborates on the potential growth aspects and restraints of this industry.

Main highlights of Biotechnology Separation Systems market report:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/65717

Geographical scrutiny of the Biotechnology Separation Systems market:

Biotechnology Separation Systems Market Segmentation: USA, Europe, Japan, China, India, South East Asia.

Key insights presented in the report with respect to the regional outlook:

A thorough analysis of Biotechnology Separation Systems market with respect to the product landscape and application spectrum:

Product landscape:

Product types:

Application landscape:

Other takeaways of Biotechnology Separation Systems market report:

Additional insight on the competitive outlook of the Biotechnology Separation Systems market:

Vendor base of the industry:

Vital parameters which define the competitive landscape of the Biotechnology Separation Systems market:

The study objectives are:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/65717

More:
Biotechnology Separation Systems Market: Worldwide Industry to Boost in the Period of 2020-2025 - Express Journal

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global Plant Derived Protein market. The study report covers all the recent developments and innovations in the market for a Plant Derived Protein. There are many government bodies, regulatory associations and universities are extending their help in the form of funds, investments and grants to promote research into the development of products of global Plant Derived Protein market. These activities of researching and funding are fuelling to the development of innovative products.

This study covers following key players:MedicagoPlanet BiotechnologyVentria BiosciencePromoCellKentucky BioprocessingAgrenvecAxol Bioscience

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4555103?utm_source=Pooja

Furthermore, Report provides the deep analysis about the impact of domestic and global players on market, trade regulation, value chain optimization, and opportunities analysis for new present as well as new players, recent developments, strategic market growth analysis, area marketplace expanding, product launches, technological innovations and many more. The study report of global Plant Derived Protein market can be split on the basis of key segments such as product type, application, key companies and key regions. Also the growth of the global Plant Derived Protein market can be projected on the basis of segments and calculation for sales by application and type of the product in terms of volume and value.

In addition, some essential tool which are needed for any market movements are stated in the report. SWOT and value chain rule analysis are studied for the global Plant Derived Protein market report. The global Plant Derived Protein market can be split on the basis of key segments such as type of the product, application, end users, key companies and key regions or countries. Report covers all the major regions and countries on the basis of product type and application. Key regions are mentioned in this report which are likely to grow at the highest CAGR over the forecast period. Report also presents the leading players which are functioning in global Plant Derived Protein market industry. Companies are presented with their company profile and their sales analysis in various regions and countries. Also report offer the growth strategies being implemented by these major large and small market players.

Access Complete Report @ https://www.orbisresearch.com/reports/index/global-plant-derived-protein-market-growth-2020-2025?utm_source=Pooja

Market segment by Type, the product can be split into Protein PolymersTherapeutic ProteinsCell Culture Functional ProteinsOthersMarket segment by Application, split into Biopharmaceutical CompanyAcademic & Research InstituteContract Research OrganizationOthers

This report provides customers with market statistics by studying the historic data and current status of the market. Also report ensures the success of user by providing comprehensive study of the market. The database is constantly updated in order to fulfil the demands of the clients. Thus report consist of a comprehensive variety of information from key industry. Report offers in depth insight on global products, industries and market trends for the customers.

Some TOC Points:

1 Industry Overview of Plant Derived Protein2 Major Manufacturers Analysis of Plant Derived Protein3 Global Price, Sales and Revenue Analysis of Plant Derived Protein by Regions, Manufacturers, Types and ApplicationsContinued

For Enquiry before buying report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4555103?utm_source=Pooja

Some TOC Points:1 Scope of the Report2 Executive Summary3 Global Plant Derived Protein by Company4 Plant Derived Protein by RegionsContinued

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Continued here:
Global Plant Derived Protein Market anticipated grow at a CAGR of xx% over the forecast period 2020-2025 :Medicago, Planet Biotechnology, Ventria...

Written by Seema Chishti | New Delhi | Updated: April 26, 2020 11:22:47 am Dr Renu Swarup, Secretary, Department of Biotechnology.

The Department of Biotechnology, under the Ministry of Science And Technology, is the nodal point for all the science-based solutions India is looking for in the battle against COVID-19. Dr Renu Swarup, Secretary, Department of Biotechnology, speaks to The Indian Express on the road ahead.

What role is the Department of Biotechnology (DBT) playing on a day-to-day basis as India wades through this crisis?

Call it day-to-day, hour-to-hour or minute-to-minute. DBT is central to all the science around COVID. Healthcare solutions, diagnostics, vaccines or therapeutics, we are the nodal agency, and this is not just about funding. COVID has set a very clear example of how the government is looking at science and its role of facilitation. We are bringing the countrys scientists on various platforms, institutions, clearing regulatory pathways. We enable coordination. BIRAC (Biotechnology Industry Research Investment Council) has been central to assisting start-ups and connecting them to investors and investments. Now, with the economic crisis, start-ups are facing more challenges and our role has become more critical.

There are 16 proposals under consideration for vaccines, diagnostics and other COVID-related solutions. Could you elaborate on them?

We invited proposals and received about 500 so far, for all aspects of managing diagnostics, therapeutics, vaccines and other resources. There are two proposals which will look at vaccines. We are continuing to screen other proposals. There are 16 in the first tranche that has been cleared. They include plasma therapy models, proposals for vaccines.

Anything more on indigenous testing?

DBT has supported a number of start-ups and research groups. Two of our indigenous start-ups are now approved for manufacturing PCR kits, and in addition, a number of them are developing Rapid Antibody Tests. We have supported a national manufacturing facility at AMTZ (Andhra Pradesh Medtech Zone) Visakhapatnam for kits and ventilators.

There are only two sequences of the virus that India has shared with the worlds database?

We have shared about nine sequences with the world database. Large scale sequencing efforts are starting now. Currently we have no conclusions about what we have in India and if the virus has mutated, but ICMR is looking into it, we are using the global data of thousands of sequences.

Work is happening in Delhi and Hyderabad on genome sequencing of Sars-Cov-2. CCMB Hyderabad and IGIB New Delhi first started working together to study the sequencing?

Those institutes apart, there are six other DBT institutes involved in the work. National Institute of Biomedical Genomics (NIBMG) in Kalyani (near Kolkata), Institute for Stem Cell Science and Regenerative Medicine (inStem), Bengaluru, Institute of Life Sciences, Bhubaneswar (ILS) and Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram (RGCB) are playing a key role along with CCMB in Hyderabad and IGIB in New Delhi in the sequencing of the genome of Sars-Cov-2.

In terms of opening the lockdown, what do you see when you look ahead?

That comes under the remit of the Health Ministry, I have nothing to say.

On a different note, where is Genome India currently?

Collection of samples is not happening at the moment. But all other work in the laboratories, in the planning, computational models, continues as before.

Genome Indias second stage was meant to be collecting samples from the population which are disease-based. Any changes to that plan, a bid to fast-track the disease-based collections now, in the wake of COVID?

No, nothing yet. We will get there as we had planned.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

The Indian Express (P) Ltd

Go here to see the original:
COVID has set example of how govt is looking at science, its role of facilitation - The Indian Express

iNtRON Biotechnology, Inc. (KOSDAQ:048530) shareholders should be happy to see the share price up 13% in the last month. But over the last half decade, the stock has not performed well. In fact, the share price is down 34%, which falls well short of the return you could get by buying an index fund.

View our latest analysis for iNtRON Biotechnology

Given that iNtRON Biotechnology didnt make a profit in the last twelve months, well focus on revenue growth to form a quick view of its business development. When a company doesnt make profits, wed generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

While the broader market lost about 11% in the twelve months, iNtRON Biotechnology shareholders did even worse, losing 33%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case theres a good opportunity. Unfortunately, last years performance may indicate unresolved challenges, given that it was worse than the annualised loss of 8.1% over the last half decade. We realise that Baron Rothschild has said investors should buy when there is blood on the streets, but we caution that investors should first be sure they are buying a high quality business. Its always interesting to track share price performance over the longer term. But to understand iNtRON Biotechnology better, we need to consider many other factors. Take risks, for example iNtRON Biotechnology has 2 warning signs we think you should be aware of.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on KR exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the article here:
Introducing iNtRON Biotechnology (KOSDAQ:048530), The Stock That Dropped 34% In The Last Five Years - Simply Wall St

Its a great moment for big food, big ag, and industry to do a self reflection and analysis of, how did we arrive here? How did we arrive to a world where the folks that picked the produce out of the field dont have access and or make enough to buy the very produce that theyre picking? Rolando Perez, graduate student and volunteer at Xinampa

Biotechnology is on the precipice of changing our world forever. Using solutions always there in biology and optimizing them with technology, biotech promises to solve global issues such as carbon emissions, plastic and chemical pollution, and, of course, feeding a booming population. But to really solve the issue of food, the industry needs to revolutionize more than just biology or technology. It needs to revolutionize the way it engages local cultures and economies. It will not be an easy task, a straightforward task, or a quick task. But it can be done and the people of the world depend on it being done right.

Climate change and population growth have led to predictions that the global population will reach nearly 10 billion people by 2050. Current food production processes cant keep pace with that growth. Fearing an existential crisis, several companies have adopted a tag line that goes something like this: we will feed the world through innovative biotechnologies that are more sustainable and make healthy food more accessible. And theyve got the sustainability beat down: from leveraging microbes to feed plants and reduce toxic nitrogen run-off to improved aquaculture techniques to genetic engineering foods to be more nutritious, the possibilities for producing ever more nutritious food while using less of the Earths precious resources are boundless and already in motion.

But what, exactly, does it mean for food to be accessible in todays world?

Food desert a term used to describe areas with limited access to affordable and nutritious food is the label by which weve come to describe food accessibility today. But the term is a bit of a misnomer, says Garrett Broad, author of More Than Just Food.

It suggests theres nothing there and if food deserts are the problem, the solution sounds pretty simple: just bring [stuff] to the desert.

But is there really nothing there? According to a recent New York Times exposition on the obesity epidemic in Brazil (and in big industrys role in that), there are now more obese people in the world than underweight people. Its as if the pendulum has swung the other direction where hunger was once a very real problem as a result of access to food, period, now obesity, diabetes, and heart disease prevail as a result of access to high calorie, nutrient-poor foods. This has created a new type of malnutrition, write Andrew Jacobs and Matt Richtel, one in which a growing number of people are both overweight and undernourished.

So, continues Broad, the problem isnt food deserts [per se], the problem is really a legacy and generational disinvestment in and direct discrimination in not just food but in a variety of other arenas. [This] calls for a broader set of solutions.

Said another way, the issue of food accessibility is multi-faceted and therefore cannot be solved solely through biotechnology we must come to terms with that fact at the get go. That isnt to say biotechnology cant make the food production system as a whole better. With advances in gene editing and other technologies, we can use technology to improve the nutritional profile of food (tackling malnutrition), to enable seasonable crops to be available all year round (increasing accessibility in one sense), to remove undesired characteristics such as cherry pits (increasing accessibility in another sense), and to make food more resistant to drought, one of the biggest factors influencing a significant proportion of the world populations access to food. But none of this matters if we keep operating under our current system, which, according to Broad, bottom-lines on profit margins, not on feeding people healthily and sustainably.

The biotechnological revolution can give the food industry and low-income disadvantaged communities a chance to hit the reset button to learn from the current state of affairs and prevent the inevitable shortfall of the big promises being made by biotechnology today if we dont change the societal, political, and economic backbone of the way food is made and distributed. And according to Ana Ibarra and Rolando Perez, volunteers at Salinas Valley-based Xinampa (a bio-hub aiming to support equitable economic development, workforce development, small business incubation, and scientific literacy and education), such sea change will come from getting people from all walks of life to sit down together and talk.

From left: Steven Rhyans, Anna Ibarra-Castro, Leo Tejeda, Omar Perez, Matias Kaplan, Rolando Perez. Photo credit: Steven Rhyans

Many of the communities most affected by food inequality are disadvantaged, underrepresented cultural and ethic groups, such as the Hispanic/Latinx and indigenous populations served by Xinampa. Salinas, California, where Xinampa is based, is over 75% Hispanic or Latinx and it is this population that is the life blood of one of the richest agricultural areas in the world. Xinampa is especially passionate about teaching young people high school and college students how they can use biotechnology in their future careers and to bolster their local communities. Ibarra says that young people will be critical for speeding up the development of technologies, a crucial goal given the issues we have at a global scale to sustain human life in light of climate change, decreasing arable land. The younger generations have the ability and talent to carry this forward, she says, and I believe its crucial to start engagement at a young age.

But, Perez is careful to point out, it isnt just about reaching the young.

The work here is intergenerational, and thats really important. There has to be engagement across the whole intergenerational spectrum the bio belt could be about finding opportunities for retirees to do things in the community plant gardens that produce nutritious produce for the community, for example. The next generation is like the seventh generation. You can say seven generations in the future, seven generations in the past, or you can strategically place yourself in the middle of those seven generations; something I learned from a close friend and that has helped me understand my role as a community member and citizen of our planet.

Emphasizing culture and recognizing that the community as a whole, and in particular indigenous communities, has deep-seeded, critical knowledge about agriculture is a core value of Xinampa. Instead of feeding people the all-too-often heard script of you guys just dont know anything, youre eating unhealthy, and were here to change you, they recognize and encourage the generations of knowledge and cultural richness that will be critical for effectively governing and incorporating biotechnology into our future food systems.

What the most successful groups that work around food at the grassroots level do is they push past those scripts, and they open up some storytelling about peoples cultural histories through food, says Broad, and that allows folks to claim knowledge about food and cooking and agriculture, which makes them much more likely to have ownership in this whole conversation.

And the whole conversation must also engage policy makers, those involved in the public health care system, industry leaders essentially anyone that could be affected by biotechnology.

One of the solutions that we could employ to address these inequities is to look to the expertise of individuals in public health, policy, social welfare, or other disciplines that are exposed to issues through a different lens and can provide a different point of view, says Ibarra, adding that its important to foster interdisciplinary conversation early on. We dont want to miss something. We dont want to invest in a solution that may not be the most effective simply because you forgot to include someone in the conversation. Early engagement is how these nutritious and novel foods will be cultivated from the ground up for the benefit of everyone in society.

One of the reasons early involvement in conversation will enable effective distribution of food to everyone is rooted in money. According to Broad, one of the biggest reasons why mistrust in GMOs and how GMO foods could solve some big problems isnt because companies havent been transparent. Its because people look at the big players, the companies in charge, and see companies that havent made their lives substantively better. People recognize that priorities within the biotech industry have not necessarily always been first and foremost about feeding the world equitably and sustainably but instead about who profits from certain biotechnological developments, says Broad. This erodes trust rather than building it.

A great way to build long standing trust is to have equitable distribution of the material wealth that gets created from these innovations. Essentially, how do we think about the development of these tools in an equitable and inclusive way in terms of economic development and economic opportunity? The best way to do this is to get people involved from early on and give them an economic stake so you develop companies that people are engaged in and involved in. That would be something for entrepreneurs and communities like [SynBioBeta] to be thinking about from an early stage, as opposed to thinking about it as kind of a PR approach that comes at the very end.

Its the economy stupid, he continues. Its that classic line if people can see that their economic and social life is going to benefit from these new innovations, then theyre much more likely to be interested in supporting them and have less fear, he says.

Ibarra agrees.

There is a lot of fear around automation and AI, including in communities like ours where the fear is robots are going to come in and pick produce and there will be less jobs for our laborers, she says. But I think the opportunities deriving from biotechnology have an even greater potential. In Monterey County we have a very robust economy resulting from direct and indirect agricultural jobs, but also a significant multiplier effect. If we couple new agricultural technologies, such as automation and AI, with biotechnology in parallel, you can see this allowing communities especially rural ones to be more resilient. Its a real opportunity.

This is critical for communities like Salinas Valley, where homelessness rates in elementary schools can be as high as 50 percent. According to Ibarra, agricultural communities like Salinas are the perfect place to cultivate regenerative biotechnologies that enrich our food systems and advance public health. She and Perez imagine a future for Salinas Valley completely transformed by biotechnology rooted in racial and class equity and justice. For example, Central Coast residents could create public interest biotechnologies that emphasize community control and governance, with investment in people, infrastructure, automation, and supply-chains that extend into the community and that connect to the Valleys world-class global supply-chains. Biotechnology can also be leveraged to produce nutritious crop varieties that adapt plant morphology to make harvesting by hand easier or gene drives to combat invasive pests such as the Asian Citrus Psyllid. Animal agriculture could benefit as well, with new veterinary biotechnological tools to better care for livestock and protect them from disease. Water systems could benefit as well, from cleaning the Salinas River through mycoremediation to employing biosensors to monitor city water for pollution, pesticides, and other chemicals.

In December 2019, Golden Rice was approved for direct use in the Philippines the first Asian country to grant the controversial food approval. Some expect that the added Vitamin A present in the rice will reduce by up to 50% vitamin A deficiency, the leading cause of child mortality in the country. But, others are skeptical that the rice will be the simple solution Filipinos have been waiting for, pointing out that vitamin A deficiency is a complex problem partially rooted in culture, political economics, education, and access. In essence, Golden Rice is the perfect example of both the promise of biotechnology in agriculture and its shortcomings if we dont think critically about all sides of the issue. With up and coming companies like Pairwise Plants and others using biotechnology to produce food that is more nutritious and can be available year-round, it is critical that we heed voices like Broad, Ibarra, and Perez so that technologies that can really make a difference in how we feed the world dont meet the same fate as Golden Rice.

It is possible to feed the world with biotechnology. But its only possible if our goal isnt to feed the world, but to engage local communities, support early, equitable, and inclusive communication, and to ensure that food equity doesnt just mean that everyone can afford to buy healthy food, but that the communities producing that food have equitable economic stake. Move over, big ag its time to take biotechnology from farm to table.

Read the original post:
Why biotech's goal should not be to feed the world - SynBioBeta